Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.…
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics (NASDAQ: DYN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 322 employees.
The shares were at 15.50 USD on 20 November 2026, down 15.6% over 52 weeks. Its 52-week range is 14.00 USD to 27.30 USD: the price is 43.2% below the high and 10.7% above the low.
Its market capitalisation is 2.90B USD.
Dyne Therapeutics reports return on equity of -45.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 890.10M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 34.33 USD is 121.5% above the current price. The next earnings report is expected on 1 March 2027.